|Bid||10.78 x 800|
|Ask||10.79 x 1300|
|Day's range||10.57 - 10.99|
|52-week range||6.25 - 13.30|
|Beta (5Y monthly)||1.46|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||12.35|
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) highlights results from the in vitro study "Migraine Therapeutics Differentially Modulate the CGRP Pathway," which were published online by Cephalalgia, a monthly journal published on behalf of the International Headache Society. These results will also be featured in a future print issue of the journal. This study demonstrated marked differences in the mechanism of blocking the calcitonin gene-related peptide (CGRP) ligand versus the CGRP receptor.
Since 2015, Teva stock has lost nearly 80% of its value in the face of loss of exclusivity on key branded drugs. In fact, Buffett still himself owns 42.8 million shares, or a 3.8% stake in the company. Will Teva be able to lead Buffett and contrarian investors alike to riches?
When I look for new investments, I'm usually looking for stocks that I think will rapidly expand for the next few years. Plus, it might be on the hook for new overhead costs pertaining to making its facilities safer in light of the risk of contagion moving forward.